Efficacy and Safety Profile of Risperidone Long-Acting Injection in Adolescents in a Real-Life Setting
Ulku AKYOL ARDIC *, Mustafa KUCUKKOSE , Sevim Berrin INCI , Eyup Sabri ERCAN
1Denizli State Hospital, Department of Child and Adolescent Psychiatry, 2Aydin State Hospital, Department of Child and Adolescent Psychiatry, 3Ege University, Institute on Drug Abuse, Toxicology and Pharmaceutical Science, 4Ege University Faculty of Medicine, Department of Child and Adolescent Psychiatry
Received: November 13, 2016; Revised: May 22, 2017; Accepted: May 22, 2017; Published online: May 22, 2017.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Background RLAI was shown to be an alternative option in adult patients, but there is not available data in child and adolescents about this medication. The aim of this study is to evaluate the safety and efficiency profile of RLAI in a group of adolescents.
Methods Eleven cases with conduct disorder and severe aggressive behaviors were initiated treatment with risperidone oral form in the psychiatry of Denizli state hospital. All cases were then shifted to RLAI 25 mg injection in each 15 days due to poor compliance to oral risperidone treatment. Efficiency of treatment included indicators of clinical severity and improvement, which were evaluated by CGI-S and I. Safety evaluation was performed by using Extrapyramidal Symptoms Rating Scale, and by monitoring body weight. Follow-up visits were done at the treatment initiation, and 8th, 16th, and 24th weeks of first injection.
Results Study included 9 girls, and 2 boys, with a mean age of 14.9±1.0 years. The CGI-S scores decreased from 6.6±0.5 at the beginning to 2.2±1.1 at the last visit (p<0.001), which is a very significant decrease through better clinical level. The CGI-I scores were also improved significantly from 2.4±0.5 to 1.9±0.5 at 24th week (p=0.001). Safety parameters were also showed favorable results, which there was no significant weight gain (p=0.076), and well-tolerated extrapyramidal adverse effects.
Conclusion Our results showed that RLAI is an efficient and safe medication option in the treatment of psychiatric disorders and severe behavioral problems in adolescents with low-compliance to oral treatment in our cases.
Keywords: Risperidone Long-Acting Injection, conduct disorder, adolescent